This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis (PERVIDEO I)

This study has been completed.
Information provided by (Responsible Party):
C. R. Bard Identifier:
First received: June 4, 2009
Last updated: January 12, 2017
Last verified: January 2017
The study will enroll patients with angiographic evidence of in-stent restenosis of a previously placed bare-metal stent. Subjects will be treated with a Lutonix Catheter. The purpose is to investigate the feasibility, safety, and efficacy of the Lutonix Catheter in the native coronary system. Angiographic and clinical outcomes will be assessed.

Condition Intervention Phase
In-Stent Restenosis Device: Lutonix Paclitaxel-Coated Balloon Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis Within Bare-Metal Stents

Resource links provided by NLM:

Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Percent Diameter Stenosis (%DS) in the Analysis Segment [ Time Frame: 6 months ]
  • Change in Diameter Stenosis (%DS) From Post-procedure Through 6 Months [ Time Frame: 6 Months ]
    Paired change in percent diameter stenosis (%DS) in the analysis segment from post-procedure through 6 months. I.e., %DS at follow-up less %DS post procedure per patient.

Secondary Outcome Measures:
  • Late Lumen Loss [ Time Frame: 6 months ]
    Change in (loss of) lumen diameter from baseline through 6 months in the analysis segment (including the treated segment and 5mm proximal and distal).

  • MACE Rate [ Time Frame: 30 Days ]
    Major adverse coronary events (MACE), including the composite of cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR).

  • Binary Restenosis [ Time Frame: 6 Months ]
    Subjects with percent diameter stenosis >50% in the analysis segment.

Enrollment: 41
Study Start Date: June 2009
Study Completion Date: December 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lutonix Catheter Device: Lutonix Paclitaxel-Coated Balloon
Other Name: Drug Coated Balloon


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or non-pregnant/non-breast feeding Female ≥18 Years of age. Women of childbearing potential must have a negative pregnancy test within 7 days of the procedure;
  • Documented stable angina pectoris Canadian Cardiovascular Society Classification (CCSC) 1-4, unstable angina pectoris with documented ischemia (Braunwald I-II) or documented silent ischemia;
  • Previous history of native coronary bare metal stenting ≥60 days;
  • LVEF ≥25%;
  • Patient is an acceptable candidate for PTCA, stenting, and emergent CABG;
  • Patient is willing to provide informed consent and comply with follow-up visits and testing schedule;
  • Target lesion is in a native coronary with previous single bare metal stent; Stenosis is ≥50% and <100% by visual estimate or QCA prior to defined pre-dilatation;
  • Reference Vessel Diameter (RVD) is ≥2.5 and ≤3.25;
  • Target lesion is ≤40 mm in length and can be treated in its entirety by no more than 2 contiguous Lutonix Catheters;
  • Guidewire is able to cross lesion(s) and be placed in distal vessel prior to enrollment;
  • Enrollment permitted after successful treatment of 1 to 2 non-study lesions in a single other non-study vessel. Successful treatment is defined as ≤30% residual stenosis with TIMI III flow and no evidence of dissection.

Exclusion Criteria:

  • History of Stroke within past 6 months;
  • History of MI or thrombolysis within 72 hours of randomization;
  • History of previous target vessel perforation;
  • Prior vascular brachytherapy;
  • Angiographic evidence of thrombus or dissection within the target vessel;
  • Intervention of another coronary lesion <60 days before index procedure day or planned following index procedure;
  • Target lesion is in the Left Main or vessel ostium and has excessive calcification or tortuosity or involves bifurcation disease of vessel ≥2.5 mm;
  • Target lesion is planned to be treated with something other than PTCA (i.e. stent, cutting balloon, atherectomy, VBT, etc.);
  • Uncontrollable allergies to procedure medications, materials, or contrast;
  • Patient has previous stent procedure with any drug-coated or drug eluting stent device in the target coronary vessel;
  • Known sensitivity to paclitaxel or other antimitogenic agent;
  • Patient has a stent sandwich (a stench previously deployed within another stent;
  • Pre-procedure CKMB >2x ULN or positive Troponin;
  • Creatinine >2.0 mg/dl;
  • Leukocyte <3500/mL;
  • Platelet <100,000 mL or >750,000 mL;
  • Currently taking or must resume warfarin;
  • Patient is contraindicated for anti-platelet therapy or it will need to be withdrawn for a planned procedure;
  • The patient is currently participating in another investigational drug or device study that has not completed its primary endpoint or that clinically interferes with the endpoints of this study;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00916279

Onze Lieve Vrouw Ziekenhuis
Aalst, Belgium, 9300
Kerckhoff Klinik
Bad Nauheim, Germany, 61231
Westdeutsches Herzzentrum Essen
Essen, Germany
Alte Clinic Center for Cardiology
Hamburg, Germany, 22527
Herzzentrum Leipzig GmbH
Leipzig, Germany
Academic Medical Center
Amsterdam, Netherlands
Catherina Ziekenhuis
Eindhoven, Netherlands
Sint Antonius Ziehenhuis
Nieuwegein, Netherlands
Sponsors and Collaborators
C. R. Bard
Principal Investigator: Laura Mauri, MD Brigham & Women's Hospital, Boston, MA
  More Information


Responsible Party: C. R. Bard Identifier: NCT00916279     History of Changes
Other Study ID Numbers: CL0010-01
Study First Received: June 4, 2009
Results First Received: August 5, 2014
Last Updated: January 12, 2017

Keywords provided by C. R. Bard:
Bare Metal In-Stent Restenosis
Paclitaxel Coated Balloon Catheter
Drug Coated Balloon
Coronary Artery Disease

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 25, 2017